Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
about
Vaccination of the immunocompromised childInfluenza vaccination in HIV-positive subjects: latest evidence and future perspectiveImmune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy.Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adultsInfluenza and HIV: lessons from the 2009 H1N1 influenza pandemic.Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theImmunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adultsEffect of treating co-infections on HIV-1 viral load: a systematic reviewImmunogenicity and safety of intradermal influenza vaccine in immunocompromized patients: a meta-analysis of randomized controlled trials.Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohortFluarix, inactivated split-virus influenza vaccine.Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adultsAntiretroviral therapy for children: challenges and opportunities.Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.A review of influenza vaccine immunogenicity and efficacy in HIV-infected adultsInfluenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responsesBooster and higher antigen doses of inactivated influenza vaccine in HIV-infected patients.Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients.
P2860
Q22305944-78976CE5-399B-405E-8DC5-4D0446AF2909Q27007483-2BC099FE-4F75-471D-9529-4515770D9D12Q30354991-1EE045B4-7A4D-47C3-8126-0FB6BFCFA949Q30356791-23D8EDDB-BC71-475A-B61C-CEA34BCBCF75Q30362521-1DAE7AE6-48F6-48EE-B03A-6492B79C80E6Q30396846-A08C4946-2C30-4F9F-ADDA-A4FEFF1EBA99Q30404293-E8220EE8-33DB-4B06-AED1-36CE6ADC71CBQ30409595-9AFB71F4-B79C-4FC2-9DEF-50F1FC6D8DE8Q30414543-839FC3CB-A501-4EA4-B30E-99E28FE2B675Q30420821-14DE30F1-F713-4882-8673-EDD4C3E60896Q33879545-8BC15AC0-D8D3-478B-AA72-11AA0ABB8D11Q33908062-791C6FE0-4CC7-47EC-940F-DFB5319913C0Q34212799-E14684BF-EB0A-49A7-B4D5-F798530E2467Q34699094-48A86A35-1C79-45F7-B53F-73DD910F25D0Q34767216-58DCD2B7-E762-41BC-8CA7-C417CB50FC40Q35807191-5C2DC998-9093-4B94-96F7-74C0EBE8E226Q35959213-A12968C6-0065-4BE1-B722-4FB7CDE32949Q36407258-41CE138A-8CF6-4A2E-AD68-76A1F7DB065EQ36452409-ADFD83C8-9E76-41F1-A860-EB1C38E87C24Q36806770-5D4516D1-58AC-43B3-A3C4-0B9F0D8EA567Q36968260-9942A734-BEA9-44A6-983F-8B24C63BF894Q37145744-3DA3539C-98F7-4BA1-BD70-3202EC95E195Q37416103-4EA38D9D-AEFB-408F-AC36-E102164755A1Q38164661-6551B8D3-89CF-4C24-BED0-4A43BFFC805FQ40300395-6ABBA79A-6B28-484B-8D25-4FDDDCB2A970Q45425500-9C06F0B4-5093-46F9-A45C-E259A9DACEDE
P2860
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
@ast
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
@en
type
label
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
@ast
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
@en
prefLabel
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
@ast
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
@en
P2093
P1433
P1476
Safety and immunogenicity of influenza vaccination in individuals infected with HIV
@en
P2093
Alessandro R Zanetti
Antonio Boschini
Silvia Besana
P304
P356
10.1016/S0264-410X(02)00511-X
P407
P478
20 Suppl 5
P577
2002-12-01T00:00:00Z